Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Perrigo Urges Shareholders to Reject Mylan Takeover Offer

By Pharmaceutical Processing | September 17, 2015

​Perrigo urges shareholders to reject Mylan‘s $27 billion hostile takeover offer, saying it undervalues the company.

On Tuesday, Mylan took its offer directly to Perrigo’s shareholders after it had been rejected by the company. The latest offer, initially proposed last week, would give shareholders $75 in cash and 2.3 shares of Mylan N.V. stock for every Perrigo Co. share they hold.

That’s a premium of about 4 percent, based on Perrigo’s value just before the offer was announced.

Dutch drugmaker Mylan wants to combine its prescription generic drug business with Irish drugmaker’s business in over-the-counter products like vitamins, nutritional products and infant formula, and it has said the two companies would have about $15 billion in combined annual revenue. Mylan shareholders voted in favor of the acquisition last month and European Union regulators have cleared it.

Mylan offered to buy Perrigo for $205 per share in April and later increased its offer to $232.23 per share, or $34.1 billion. Perrigo said that cash-and-stock offer wasn’t worth as much as Mylan said. At the time Mylan’s stock price was elevated as an even larger generic drug company, Teva Pharmaceutical Industries Ltd., was trying to buy Mylan. Mylan fended off Teva, which decided to buy Allergan PLC’s generic drug business for $40.5 billion instead.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE